Molecular imaging of chemokine receptor CXCR4

Theranostics

Volumn 3, Issue 1, 2013, Pages 76-84

  Weiss, Ido D ^a   Jacobson, Orit ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Cancer; CXCR4; Diagnostics; Molecular imaging

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; 1,4,7 TRIAZACYCLONONANE 1,4,7 TRIACETIC ACID; ACTZ 14011; AMD 3645; CARBOXYFLUORESCEIN; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CHEMOKINE RECEPTOR CXCR7; COPPER 64; FC 131; FLUORINE 18; GALLIUM 68; INDIUM 111; IODINE 125; MSX 122; PLERIXAFOR; RADIOPHARMACEUTICAL AGENT; STROMAL CELL DERIVED FACTOR 1; T 140; TECHNETIUM 99M; TY 14003; UNCLASSIFIED DRUG;

BIOLUMINESCENCE; BLADDER CANCER; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RESISTANCE; CELL SURVIVAL; CLINICAL EVALUATION; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG HALF LIFE; DRUG TARGETING; FLUORESCENCE ANALYSIS; HUMAN; IC 50; ISOTOPE LABELING; METASTASIS; MOLECULAR IMAGING; NON INVASIVE MEASUREMENT; NONHUMAN; PERSONALIZED MEDICINE; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; RECEPTOR BLOCKING; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

CANCER.; CXCR4; DIAGNOSTICS; MOLECULAR IMAGING;

ANIMALS; FLUORESCENCE; HUMANS; LUMINESCENT MEASUREMENTS; MOLECULAR IMAGING; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, CXCR4; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84883187912     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.4835     Document Type: Review

References (55)

1. Murdoch C. CXCR4: chemokine receptor extraordinaire. Immunol Rev. 2000; 177: 175-84.
2. Horuk R. Chemokine receptors. Cytokine Growth Factor Rev. 2001; 12: 313-35.
3. Phillips RJ, Burdick MD, Lutz M, Belperio JA, Keane MP, Strieter RM. The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological biological axis in non-small cell lung cancer metastases. Am J Respir Crit Care Med. 2003; 167: 1676-86.
4. Balkwill F. The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol. 2004; 14: 171-9.
5. Peled A, Petit I, Kollet O, Magid M, Ponomaryov T, Byk T, et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science. 1999; 283: 845-8.
6. Peled A, Wald O, Burger J. Development of novel CXCR4-based therapeutics. Expert Opin Investig Drugs. 2012; 21: 341-53.
7. Furusato B, Mohamed A, Uhlen M, Rhim JS. CXCR4 and cancer. Pathol Int. 2010; 60: 497-505.
8. Tanaka T, Bai Z, Srinoulprasert Y, Yang BG, Hayasaka H, Miyasaka M. Chemokines in tumor progression and metastasis. Cancer Sci. 2005; 96: 317-22.
9. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001; 410: 50-6.
10. Redjal N, Chan JA, Segal RA, Kung AL. CXCR4 inhibition synergizes with cytotoxic chemotherapy in gliomas. Clin Cancer Res. 2006; 12: 6765-71.
11. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res. 2002; 62: 1832-7.
12. Vicari AP, Caux C. Chemokines in cancer. Cytokine Growth Factor Rev. 2002; 13: 143-54.
13. Azab AK, Runnels JM, Pitsillides C, Moreau AS, Azab F, Leleu X, et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood. 2009; 113: 4341-51.
14. Kurtova AV, Tamayo AT, Ford RJ, Burger JA. Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting. Blood. 2009; 113: 4604-13.
15. Yoon Y, Liang Z, Zhang X, Choe M, Zhu A, Cho HT, et al. CXC chemokine receptor-4 antagonist blocks both growth of primary tumor and metastasis of head and neck cancer in xenograft mouse models. Cancer Res. 2007; 67: 7518-24.
16. Li JK, Yu L, Shen Y, Zhou LS, Wang YC, Zhang JH. Inhibition of CXCR4 activity with AMD3100 decreases invasion of human colorectal cancer cells in vitro. World J Gastroenterol. 2008; 14: 2308-13.
17. Lee HJ, Kim SW, Kim HY, Li S, Yun HJ, Song KS, et al. Chemokine receptor CXCR4 expression, function, and clinical implications in gastric cancer. Int J Oncol. 2009; 34: 473-80.
18. Oda Y, Tateishi N, Matono H, Matsuura S, Yamamaoto H, Tamiya S, et al. Chemokine receptor CXCR4 expression is correlated with VEGF expression and poor survival in soft-tissue sarcoma. Int J Cancer. 2009; 124: 1852-9.
19. Rahmim A, Zaidi H. PET versus SPECT: strengths, limitations and challenges. Nucl Med Commun. 2008; 29: 193-207.
20. Hanaoka H, Mukai T, Tamamura H, Mori T, Ishino S, Ogawa K, et al. Development of a 111In-labeled peptide derivative targeting a chemokine receptor, CXCR4, for imaging tumors. Nucl Med Biol. 2006; 33: 489-94.
21. Nimmagadda S, Pullambhatla M, Pomper MG. Immunoimaging of CXCR4 expression in brain tumor xenografts using SPECT/CT. J Nucl Med. 2009; 50: 1124-30.
22. Misra P, Lebeche D, Ly H, Schwarzkopf M, Diaz G, Hajjar RJ, et al. Quantitation of CXCR4 expression in myocardial infarction using 99mTc-labeled SDF-1alpha. J Nucl Med. 2008; 49: 963-9.
23. Saleem A, Charnley N, Price P. Clinical molecular imaging with positron emission tomography. Eur J Cancer. 2006; 42: 1720-7.
24. Jacobson O, Weiss ID, Szajek L, Farber JM, Kiesewetter DO. 64Cu-AMD3100--a novel imaging agent for targeting chemokine receptor CXCR4. Bioorg Med Chem. 2009; 17: 1486-93.
25. Weiss ID, Jacobson O, Kiesewetter DO, Jacobus JP, Szajek LP, Chen X, et al. Positron emission tomography imaging of tumors expressing the human chemokine receptor CXCR4 in mice with the use of (6)(4)Cu-AMD3100. Mol Imaging Biol. 2011; 14: 106-14.
26. Nimmagadda S, Pullambhatla M, Stone K, Green G, Bhujwalla ZM, Pomper MG. Molecular imaging of CXCR4 receptor expression in human cancer xenografts with [64Cu]AMD3100 positron emission tomography. Cancer Res. 2010; 70: 3935-44.
27. Li W, Gomez E, Zhang Z. Immunohistochemical expression of stromal cell-derived factor-1 (SDF-1) and CXCR4 ligand receptor system in hepatocellular carcinoma. J Exp Clin Cancer Res. 2007; 26: 527-33.
28. Mavier P, Martin N, Couchie D, Preaux AM, Laperche Y, Zafrani ES. Expression of stromal cell-derived factor-1 and of its receptor CXCR4 in liver regeneration from oval cells in rat. Am J Pathol. 2004; 165: 1969-77.
29. Hatch HM, Zheng D, Jorgensen ML, Petersen BE. SDF-1alpha/CXCR4: a mechanism for hepatic oval cell activation and bone marrow stem cell recruitment to the injured liver of rats. Cloning Stem Cells. 2002; 4: 339-51.
30. De Silva RA, Peyre K, Pullambhatla M, Fox JJ, Pomper MG, Nimmagadda S. Imaging CXCR4 expression in human cancer xenografts: evaluation of monocyclam 64Cu-AMD3465. J Nucl Med. 2011; 52: 986-93.
31. Jacobson O, Weiss ID, Kiesewetter DO, Farber JM, Chen X. PET of tumor CXCR4 expression with 4-18F-T140. J Nucl Med. 2010; 51: 1796-804.
32. Jacobson O, Weiss ID, Szajek LP, Niu G, Ma Y, Kiesewetter DO, et al. PET imaging of CXCR4 using copper-64 labeled peptide antagonist. Theranostics. 2011; 1: 251-62.
33. Jacobson O, Weiss ID, Szajek LP, Niu G, Ma Y, Kiesewetter DO, et al. Improvement of CXCR4 tracer specificity for PET imaging. J Control Release.2012; 157: 216-23.
34. Hennrich U, Seyler L, Schafer M, Bauder-Wust U, Eisenhut M, Semmler W, et al. Synthesis and in vitro evaluation of 68Ga-DOTA-4-FBn-TN14003, a novel tracer for the imaging of CXCR4 expression. Bioorg Med Chem. 2012; 20: 1502-10.
35. Demmer O, Dijkgraaf I, Schumacher U, Marinelli L, Cosconati S, Gourni E, et al. Design, synthesis, and functionalization of dimeric peptides targeting chemokine receptor CXCR4. J Med Chem. 2011; 54: 7648-62.
36. Demmer O, Gourni E, Schumacher U, Kessler H, Wester HJ. PET imaging of CXCR4 receptors in cancer by a new optimized ligand. ChemMedChem. 2011; 6: 1789-91.
37. Gourni E, Demmer O, Schottelius M, D'Alessandria C, Schulz S, Dijkgraaf I, et al. PET of CXCR4 expression by a (68)Ga-labeled highly specific targeted contrast agent. J Nucl Med. 2011; 52: 1803-10.
38. Liang Z, Zhan W, Zhu A, Yoon Y, Lin S, Sasaki M, et al. Development of a unique small molecule modulator of CXCR4. PLoS One. 2012; 7: e34038.
39. Keyaerts M, Caveliers V, Lahoutte T. Bioluminescence imaging: looking beyond the light. Trends Mol Med. 2012; 18: 164-72.
40. Darash-Yahana M, Pikarsky E, Abramovitch R, Zeira E, Pal B, Karplus R, et al. Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis. FASEB J. 2004; 18: 1240-2.
41. Hong YL, Wu LH, Cui M, McMaster G, Hunt SW, 3rd, Chung FZ. New reporter cell lines to study macrophage-tropic HIV envelope protein- mediated cell-cell fusion. AIDS Res Hum Retroviruses. 1999; 15: 1667-72.
42. Gonzalez N, Perez-Olmeda M, Mateos E, Cascajero A, Alvarez A, Spijkers S, et al. A sensitive phenotypic assay for the determination of human immunodeficiency virus type 1 tropism. J Antimicrob Chemother. 2010; 65: 2493-501.
43. Luker K, Gupta M, Luker G. Bioluminescent CXCL12 fusion protein for cellular studies of CXCR4 and CXCR7. Biotechniques. 2009; 47: 625-32.
44. Luker KE, Lewin SA, Mihalko LA, Schmidt BT, Winkler JS, Coggins NL, et al. Scavenging of CXCL12 by CXCR7 promotes tumor growth and metastasis of CXCR4-positive breast cancer cells. Oncogene. 2012.
45. Luker KE, Mihalko LA, Schmidt BT, Lewin SA, Ray P, Shcherbo D, et al. In vivo imaging of ligand receptor binding with Gaussia luciferase complementation. Nat Med. 2011; 18: 172-7.
46. Luker KE, Gupta M, Luker GD. Imaging CXCR4 signaling with firefly luciferase complementation. Anal Chem. 2008; 80: 5565-73.
47. Leblond F, Davis SC, Valdes PA, Pogue BW. Pre-clinical whole-body fluorescence imaging: Review of instruments, methods and applications. J Photochem Photobiol B. 2010; 98: 77-94.
48. Nishizawa K, Nishiyama H, Oishi S, Tanahara N, Kotani H, Mikami Y, et al. Fluorescent imaging of high-grade bladder cancer using a specific antagonist for chemokine receptor CXCR4. Int J Cancer. 2010; 127: 1180-7.
49. Oishi S, Masuda R, Evans B, Ueda S, Goto Y, Ohno H, et al. Synthesis and application of fluorescein- and biotin-labeled molecular probes for the chemokine receptor CXCR4. Chembiochem. 2008; 9: 1154-8.
50. Meincke M, Tiwari S, Hattermann K, Kalthoff H, Mentlein R. Near-infrared molecular imaging of tumors via chemokine receptors CXCR4 and CXCR7. Clin Exp Metastasis. 2011; 28: 713-20.
51. Kuil J, Steunenberg P, Chin PT, Oldenburg J, Jalink K, Velders AH, et al. Peptide-functionalized luminescent iridium complexes for lifetime imaging of CXCR4 expression. Chembiochem. 2011; 12: 1897-903.
52. Zhang J, Fu Y, Li G, Zhao RY, Lakowicz JR. Detection of CXCR4 receptors on cell surface using a fluorescent metal nanoshell. J Biomed Opt. 2011; 16: 016011..
53. Jin T, Tiwari DK, Tanaka S, Inouye Y, Yoshizawa K, Watanabe TM. Antibody-protein A conjugated quantum dots for multiplexed imaging of surface receptors in living cells. Mol Biosyst. 2010; 6: 2325-31.
54. Kuil J, Buckle T, Oldenburg J, Yuan H, Borowsky AD, Josephson L, et al. Hybrid peptide dendrimers for imaging of chemokine receptor 4 (CXCR4) expression. Mol Pharm. 2011; 8: 2444-53.
55. Jacobson O, Weiss ID, Szajek LP, Niu G, Ma Y, Kiesewetter DO, et al. Improvement of CXCR4 tracer specificity for PET imaging. J Control Release. 2012; 157: 216-23.